医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics

2017年10月17日 PM09:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

GenePeeks, Inc., a computational genomics company focused on transforming disease risk analysis, today announced an exclusive distribution agreement with CORE Diagnostics, a next-generation diagnostics provider committed to bringing best-in-class clinical technology and innovation to India.

This new distribution agreement furthers GenePeeks’ goal of expanding access to its breakthrough preconception screen and advanced analytics platform in new markets around the world. CORE will exclusively offer GenePeeks’ preconception screen in their extensive market of twenty-nine states and seven union territories across India, greatly expanding GenePeeks global footprint.

“GenePeeks is delighted to add CORE Diagnostics to our list of outstanding global partners,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “We look forward to working with the exceptional CORE team to address the European bias embedded in traditional screening and help Indian families better understand their risk of conceiving a child with a serious genetic disease.”

Zoya Brar, co-founder and managing director of CORE Diagnostics stated, “We are excited to partner with GenePeeks to expand our portfolio of innovative testing services and support the growing interest from Indian families and their healthcare providers in preconception screening. GenePeeks’ technology provides a unique opportunity to identify risk to Indian families that was often uncharacterized historically and hidden from clinical view.”

About GenePeeks’ Screening Technology

GenePeeks’ preconception screening technology uniquely integrates DNA information from two genetic participants to predict the potential genomes of a future child. For every variant in these hypothetical genomes, the company’s proprietary platform computes a Variant Gene Dysfunction (VGD) score that predicts the degree to which any variant, known or novel, reduces normal gene function. This breakthrough approach allows GenePeeks to go beyond the limits of the clinical data to evaluate variants that remain uncharacterized by other genetic tests, particularly variants found within global populations.

About GenePeeks

GenePeeks is a computational genomics company with an automated, CLIA certified platform that is transforming how genetic disease is identified. GenePeeks’ patented, next-generation technology addresses the primary challenges of genomic analysis today, including the pervasiveness of rare and novel disease-causing mutations, the high incidence of variants of uncertain significance (VUS), and the population bias embedded in the clinical literature and databases. GenePeeks offers its physician-ordered services through its certified clinical laboratory.

GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com.

GenePeeks’ preconception screening technology is available today. For more information about becoming a partner, please contact partner@genepeeks.com.

About CORE Diagnostics

CORE Diagnostics was founded in 2012 with the goal of bringing the world’s most advanced testing techniques and expertise to India. As a next-generation clinical diagnostics lab focused on disease stratification and therapy selection, CORE provides unique diagnostics with second opinions on every test and has been growing at nearly 100% each year. With well over 1000 tests in its clinical portfolio, a panel of over 100 super specialists across the world, a coverage of over 80% of the prescriber base, CORE supports clinicians in identifying a definitive diagnosis for their patients as quickly as possible. For more information, visit www.corediagnostics.in.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171017006000/en/

CONTACT

Feinstein Kean Healthcare
Lisa Rivero, 617-761-6746
Lisa.Rivero@fkhealth.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • NAMSA推出中文网站,为亚太区赞助商提供医疗器械开发资源
  • 从小众到常态——大麻的使用在美国被更多人接受
  • ニッチ層から一般層へ:米国でカナビスの使用がさらに認知される流れ
  • Dr. Reddy’s Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation
  • CDISC Releases Therapeutic Area User Guide to Bring Clarity to Data for Colorectal Cancer Research